Back to top

Analyst Reiterates Buy on Xtant, Citing BioHorizons Partnership and High-Margin OsteoFactor Pro as Key Growth Drivers

Analyst Naz Rahman of Maxim Group reiterated a Buy rating on Xtant Medical Holdings, with a price target of $1.50. Naz Rahman has given his Buy rat...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Xtant Medical Holdings, Inc. (XTNT)